Pfizer, Sanofi Forge Deals Worth Over USD 2.6b in Autoimmune Space

Pharma majors Pfizer and Sanofi announced separate significant collaborations in the autoimmune disease sector on 15 December, with a combined potential transaction value exceeding USD 2.6 billion. Pfizer has entered into an agreement with Adaptive Biotechnologies, valued at up to USD 890 million, to leverage Adaptive's AI-driven immunomics platform and T-cell receptor (TCR) data for identifying pathogenic T-cell targets in rheumatoid arthritis (RA). The deal includes an upfront payment, milestone payments and a separate TCR data licensing component for training Pfizer's internal AI models.

Sanofi, building on its earlier acquisition of Dren Bio's lymphoma candidate, has expanded its partnership with the biotech firm to develop next-generation B-cell-depleting therapies for autoimmune diseases. The new agreement provides Dren with a USD 100 million upfront payment and potential milestone payments of up to USD 1.7 billion. Notably, Dren holds an option to co-fund 40% of global development costs in exchange for co-promotion rights and a 50/50 profit share in the US market. 

According to PharmCube's NextBiopharm® database, Big Pharma has struck nearly 40 immunology deals this year, with Sanofi leading with 8 transactions. Click here to request a free trial for NextBiopharm®.

Daily News
Lilly Announces USD 3b Investment in China to Bolster Local Supply Chain
2026-03-12
UCB's Bimekizumab Demonstrates Superiority to Risankizumab in PsA
2026-03-12
Laekna's ActRIIA Inhibitor Shows Promising Muscle Gain, Fat Loss
2026-03-11
Pfizer's First-in-Class TsAb Succeeds in Phase II Atopic Dermatitis Trial
2026-03-11
Hansoh's GLP-1/GIP Dual Agonist Shows 19.3% Weight Loss in Phase III
2026-03-10
Latest Report
Global Drug Progress Report during January 2026
Details